QQQ   323.59 (+3.01%)
AAPL   127.79 (+5.39%)
MSFT   236.94 (+1.96%)
FB   264.91 (+2.83%)
GOOGL   2,069.66 (+2.36%)
TSLA   718.43 (+6.36%)
AMZN   3,146.14 (+1.72%)
NVDA   553.67 (+0.93%)
BABA   241.69 (+1.65%)
CGC   34.73 (+6.05%)
GE   13.11 (+4.55%)
MU   94.76 (+3.53%)
NIO   49.76 (+8.69%)
AMD   86.39 (+2.22%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.64 (+2.19%)
BAC   35.79 (+3.11%)
QQQ   323.59 (+3.01%)
AAPL   127.79 (+5.39%)
MSFT   236.94 (+1.96%)
FB   264.91 (+2.83%)
GOOGL   2,069.66 (+2.36%)
TSLA   718.43 (+6.36%)
AMZN   3,146.14 (+1.72%)
NVDA   553.67 (+0.93%)
BABA   241.69 (+1.65%)
CGC   34.73 (+6.05%)
GE   13.11 (+4.55%)
MU   94.76 (+3.53%)
NIO   49.76 (+8.69%)
AMD   86.39 (+2.22%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.64 (+2.19%)
BAC   35.79 (+3.11%)
QQQ   323.59 (+3.01%)
AAPL   127.79 (+5.39%)
MSFT   236.94 (+1.96%)
FB   264.91 (+2.83%)
GOOGL   2,069.66 (+2.36%)
TSLA   718.43 (+6.36%)
AMZN   3,146.14 (+1.72%)
NVDA   553.67 (+0.93%)
BABA   241.69 (+1.65%)
CGC   34.73 (+6.05%)
GE   13.11 (+4.55%)
MU   94.76 (+3.53%)
NIO   49.76 (+8.69%)
AMD   86.39 (+2.22%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.64 (+2.19%)
BAC   35.79 (+3.11%)
QQQ   323.59 (+3.01%)
AAPL   127.79 (+5.39%)
MSFT   236.94 (+1.96%)
FB   264.91 (+2.83%)
GOOGL   2,069.66 (+2.36%)
TSLA   718.43 (+6.36%)
AMZN   3,146.14 (+1.72%)
NVDA   553.67 (+0.93%)
BABA   241.69 (+1.65%)
CGC   34.73 (+6.05%)
GE   13.11 (+4.55%)
MU   94.76 (+3.53%)
NIO   49.76 (+8.69%)
AMD   86.39 (+2.22%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.64 (+2.19%)
BAC   35.79 (+3.11%)
Log in
NASDAQ:SNDX

Syndax Pharmaceuticals Stock Forecast, Price & News

$24.15
-0.26 (-1.07 %)
(As of 03/1/2021 12:00 AM ET)
Add
Compare
Today's Range
$23.79
Now: $24.15
$25.17
50-Day Range
$19.28
MA: $22.03
$24.59
52-Week Range
$6.88
Now: $24.15
$27.85
Volume688,338 shs
Average Volume567,565 shs
Market Capitalization$986.99 million
P/E RatioN/A
Dividend YieldN/A
Beta1.8
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's lead product candidates are entinostat that is in Phase III clinical trials for the treatment of advanced hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer; and SNDX-5613 in Phase I/II clinical trial inhibitor that targets the binding interaction of Menin with mixed lineage leukemia-rearranged and acute myeloid leukemia with a mutated nucleophosmin 1. It also develops entinostat with Keytruda (pembrolizumab) in a Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and melanoma or microsatellite stable colorectal carcinoma; and with Tecentriq (atezolizumab) in Phase Ib/II clinical trials to treat patients with HR+ and HER2- metastatic breast cancer. In addition, the company develops SNDX-6352, a monoclonal antibody that blocks the colony stimulating factor 1 that is in Phase I/II clinical trial in patients with chronic graft versus host disease; and as a monotherapy and in combination with Imfinzi (durvalumab), which is completed Phase Ib dose trials for the treatment of solid tumors. Syndax Pharmaceuticals, Inc. has clinical collaborations with MSD International GmbH; Genentech, Inc.; and Merck KGaA and Pfizer. It also has collaborative research and development agreement with National Cancer Institute; clinical trial agreement with Eastern Cooperative Oncology Group; and license agreement with Kyowa Hakko Kirin Co., Ltd. The company was founded in 2005 and is headquartered in Waltham, Massachusetts.
Syndax Pharmaceuticals logo

Headlines

Syndax Pharmaceuticals, Inc. to Host Earnings Call
November 2, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SNDX
CUSIPN/A
Phone781-419-1400
Employees35
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.52 million
Book Value$1.16 per share

Profitability

Net Income$-56,050,000.00
Net Margins-4,656.63%

Miscellaneous

Market Cap$986.99 million
Next Earnings Date3/2/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.64 out of 5 stars

Medical Sector

284th out of 1,965 stocks

Pharmaceutical Preparations Industry

134th out of 772 stocks

Analyst Opinion: 3.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$24.15
-0.26 (-1.07 %)
(As of 03/1/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SNDX News and Ratings via Email

Sign-up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Syndax Pharmaceuticals (NASDAQ:SNDX) Frequently Asked Questions

Is Syndax Pharmaceuticals a buy right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Syndax Pharmaceuticals stock.
View analyst ratings for Syndax Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Syndax Pharmaceuticals?

Wall Street analysts have given Syndax Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Syndax Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Syndax Pharmaceuticals' next earnings date?

Syndax Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 2nd 2021.
View our earnings forecast for Syndax Pharmaceuticals
.

How were Syndax Pharmaceuticals' earnings last quarter?

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) issued its earnings results on Monday, November, 2nd. The company reported ($0.46) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.42) by $0.04. The firm had revenue of $0.38 million for the quarter. Syndax Pharmaceuticals had a negative net margin of 4,656.63% and a negative trailing twelve-month return on equity of 77.47%.
View Syndax Pharmaceuticals' earnings history
.

How has Syndax Pharmaceuticals' stock been impacted by COVID-19?

Syndax Pharmaceuticals' stock was trading at $11.79 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SNDX shares have increased by 104.8% and is now trading at $24.15.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for SNDX?

12 brokers have issued twelve-month price objectives for Syndax Pharmaceuticals' shares. Their forecasts range from $15.00 to $33.00. On average, they anticipate Syndax Pharmaceuticals' stock price to reach $27.50 in the next year. This suggests a possible upside of 13.9% from the stock's current price.
View analysts' price targets for Syndax Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Syndax Pharmaceuticals' key executives?

Syndax Pharmaceuticals' management team includes the following people:
  • Dr. Briggs W. Morrison M.D., CEO & Director (Age 61, Pay $848.43k)
  • Mr. Michael A. Metzger, Pres, COO & Director (Age 50, Pay $795.35k)
  • Dr. Michael L. Meyers, Chief Medical Officer & Sr. VP (Age 70, Pay $599.3k)
  • Dr. Peter Ordentlich, Co-Founder & Chief Scientific Officer (Age 52)
  • Dr. Richard A. Heyman, Co-Founder (Age 64)
  • Dr. Ronald M. Evans Ph.D., Co-Founder, Advisor and Chair of Scientific Advisory Board
  • Dr. Michael Downes Ph.D., Co-Founder
  • Ms. Daphne Karydas M.B.A., Chief Financial Officer (Age 48)
  • Mr. Luke J. Albrecht, Sr. VP, Gen. Counsel & Sec. (Age 42)
  • Dr. Edward A. Sausville M.D., Ph.D., Advisor

Who are some of Syndax Pharmaceuticals' key competitors?

What other stocks do shareholders of Syndax Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syndax Pharmaceuticals investors own include OPKO Health (OPK), Exelixis (EXEL), Verastem (VSTM), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Idera Pharmaceuticals (IDRA), TherapeuticsMD (TXMD) and Micron Technology (MU).

When did Syndax Pharmaceuticals IPO?

(SNDX) raised $66 million in an initial public offering on Thursday, March 3rd 2016. The company issued 4,400,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Citigroup served as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.

What is Syndax Pharmaceuticals' stock symbol?

Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNDX."

Who are Syndax Pharmaceuticals' major shareholders?

Syndax Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Avidity Partners Management LP (8.09%), BlackRock Inc. (5.68%), Frazier Management LLC (3.44%), Ghost Tree Capital LLC (3.30%), Orbimed Advisors LLC (2.87%) and Dimensional Fund Advisors LP (1.90%). Company insiders that own Syndax Pharmaceuticals stock include Briggs Morrison, Michael A Metzger, Michael L Meyers and Peter Ordentlich.
View institutional ownership trends for Syndax Pharmaceuticals
.

Which institutional investors are selling Syndax Pharmaceuticals stock?

SNDX stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Dimensional Fund Advisors LP, Nuveen Asset Management LLC, Russell Investments Group Ltd., GSA Capital Partners LLP, Trexquant Investment LP, Virtus ETF Advisers LLC, and State of Wisconsin Investment Board. Company insiders that have sold Syndax Pharmaceuticals company stock in the last year include Michael A Metzger, and Peter Ordentlich.
View insider buying and selling activity for Syndax Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Syndax Pharmaceuticals stock?

SNDX stock was purchased by a variety of institutional investors in the last quarter, including Avidity Partners Management LP, Ghost Tree Capital LLC, Avoro Capital Advisors LLC, BlackRock Inc., Acuta Capital Partners LLC, Price T Rowe Associates Inc. MD, Janus Henderson Group PLC, and Tri Locum Partners LP. Company insiders that have bought Syndax Pharmaceuticals stock in the last two years include Briggs Morrison, and Michael L Meyers.
View insider buying and selling activity for Syndax Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Syndax Pharmaceuticals?

Shares of SNDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Syndax Pharmaceuticals' stock price today?

One share of SNDX stock can currently be purchased for approximately $24.15.

How much money does Syndax Pharmaceuticals make?

Syndax Pharmaceuticals has a market capitalization of $986.99 million and generates $1.52 million in revenue each year. The company earns $-56,050,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis.

How many employees does Syndax Pharmaceuticals have?

Syndax Pharmaceuticals employs 35 workers across the globe.

What is Syndax Pharmaceuticals' official website?

The official website for Syndax Pharmaceuticals is www.syndax.com.

Where are Syndax Pharmaceuticals' headquarters?

Syndax Pharmaceuticals is headquartered at 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451.

How can I contact Syndax Pharmaceuticals?

Syndax Pharmaceuticals' mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The company can be reached via phone at 781-419-1400 or via email at [email protected]


This page was last updated on 3/1/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.